Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt, 
consult the original text.
The slimming based sibutramine continue with the sale released in the country. The decision on Monday (27) is the executive board of the National Agency for Sanitary Surveillance (ANVISA). The regulatory agency monitored the drug over the past year.
In 2011, ANVISA decided to banish the slimming-based amfepramone femproporex and mazindol, called amphetamines. Already sibutramine remained released, but with restrictions. Patients and physicians must sign a liability waiver, presented along with the prescription at the time of purchase.
Resolution 52, 2011, ANVISA, determined that health professionals, companies holding registration and pharmacies must notify compulsorily the National Health Surveillance in cases of adverse effects associated with the use of drugs with sibutramine.
In March, the CEO of ANVISA, Dirceu Barbano, declared that there was no reason to ban the sale of the substance, since studies done by the agency indicated no increase in the use of sibutramine, even with the prohibition of other diet pills.
Palavras-chave: Sibutramine
National Health Surveillance Agency
ANVISA
Amfepramone femproporex
Mazindol
Amphetamine
National Sanitary Surveillance System
Dirceu Barbano
Share this page
Correct
Share
Alert
